Pharmaceutical composition comprising glucopyranosyl diphenylmethane derivatives, pharmaceutical dosage form thereof, process for their preparation and uses thereof for improved glycemic control in a patient

Details for Australian Patent Application No. 2010212868 (hide)

Owner Boehringer Ingelheim International GmbH

Inventors Eisenreich, Wolfram; Ladyzhynsky, Nadia S.; Li, Danping; Schultz, Leon; Wang, Zeren; Macha, Sreeraj; Barta, Albert

Agent Spruson & Ferguson

Pub. Number AU-A-2010212868

PCT Pub. Number WO2010/092126

Priority 61/152,317 13.02.09 US; 61/254,033 22.10.09 US

Filing date 11 February 2010

Wipo publication date 19 August 2010

International Classifications

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61K 9/16 (2006.01) Medicinal preparations characterised by special physical form - Agglomerates

A61K 9/20 (2006.01) Medicinal preparations characterised by special physical form - Pills, lozenges or tablets

A61K 31/431 (2006.01)

A61K 31/7004 (2006.01) - Monosaccharides having only carbon, hydrogen and oxygen atoms

A61P 3/04 (2006.01) Drugs for disorders of the metabolism

A61P 3/06 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

Event Publications

8 September 2011 PCT application entered the National Phase

  PCT publication WO2010/092126 Priority application(s): WO2010/092126

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010212874-Method and system for adjusting the flow rate of charge material in a charging process of a shaft furnace

2010212867-Pharmaceutical composition comprising a SGLT2 inhibitor, a DPP-IV inhibitor and optionally a further antidiabetic agent and uses thereof